← Eichor
Study identifier: NCT05093153 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Spanish Registry of Patients With IgM Monoclonal Gammopathies

Condition: Waldenstrom Macroglobulinemia  ·  Sponsor: Fundación Española de Hematología y Hemoterapía

PhaseN/A
Planned participants1000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Waldenström's macroglobulinemia (WM) is a B-cell lymphoproliferative disorder which is defined by bone marrow infiltration by small lymphocytes, lymphoplasmacytoid and plasma cells together with the presence of a detectable monoclonal immunoglobulin M (IgM).The clinical presentation of WM is variable. Symptoms can be related to tumor infiltration, or they can be related to the monoclonal IgM component. The therapeutic options are heterogeneous and there are no well-established in both first line or relapse/refractory settings. In Spain, the incidence of MGUS-IgM and WM in the last decade is unknown. The aims of this retrospective, observational, multicentric study is: * To develop a national registry of patients diagnosed with Waldenström's Macroglobulinemia and Monoclonal Gammopathy of uncertain significance -IgM in Spain in the past 30years. * To evaluate the most relevant clinical characteristics, long-term safety and efficacy of different therapeutic schemes and long-term prognosis of patients with WM * To help in the design of future therapeutic strategies, risk prognostic factors and clinical trials in Spain. Methods: The investigators will collect data from the patient clinical files after prior Informed Consent providing from patients with diagnosis of MGUS-IgM and WM in the past 30 years in Spain, according to the WHO classification of lymphoid tumors (2008) revised in 2016. Data from patients not able to provide IC (i.e., already dead patients) will be included …

This description comes directly from the study's public registry record.

Talk to the study team

RAMON GARCIA SANZ, MD  ·  +34 915868000  ·  rgarcias@usal.es

ELHAM ASKARI ASKARI, MD  ·  +34 915504800  ·  easkari@fdj.es

Always discuss trial participation with your own doctor first.

Locations (51)

Hospital de MéridaMérida, Badajoz, SpainRecruiting
Hospital Son LlatzerPalma, Balearic Islands, SpainRecruiting
Hospital Universitario Son EspasesPalma de Mallorca, Balearic Islands, SpainRecruiting
ICO Badalona - Hospital Germans Trias i PujolBadalona, Barcelona, SpainRecruiting
Hospital Mutua TerrassaBarcelona, Barcelona, SpainRecruiting
Hospital de San Juan Despí Moisès BroggiBarcelona, Barcelona, SpainRecruiting
Hospital Clínic de BarcelonaBarcelona, Barcelona, SpainRecruiting
Hospital del MarBarcelona, Barcelona, SpainRecruiting
Hospital Vall d'HebronBarcelona, Barcelona, SpainRecruiting
Hospital Sant Joan de Déu de ManresaManresa, Barcelona, SpainRecruiting
Hospital Parc TaulíSabadell, Barcelona, SpainRecruiting
Hospital Universitario Reina SofíaCórdoba, Córdoba, SpainRecruiting

+ 39 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05093153